N/A N=20 Effects of Cardiac Rehabilitation for Individuals With Transient Ischemic Attack
Transient Ischemic Attack
Primary: Functional Walk Test — 498.4; 503.2; 564.2 meters — p==0.06
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=1,274 A Randomized Controlled Trial of TNK-tPA Versus Standard of Care for Minor Ischemic Stroke With Proven Occlusion
Stroke, Acute
Primary: Number of Participants With Return to Baseline Neurological Functioning Measured by the Modified Rankin Scale (mRS) — 309; 338 Participants
N/A N=30 Stroke Education Intervention Trial - Pilot
Ischemic Stroke · Intracranial Hemorrhage · Transient Ischemic Attack
Primary: Feasibility of Intervention (Ability to Reach Patients at 3 Months) — 16; 10 number of patients contacted
N/A N=82 Vertebrobasilar Flow Evaluation and Risk of Transient Ischemic Attack and Stroke (VERiTAS)
Vertebrobasilar Insufficiency · Ischemic Attack, Transient · Cerebrovascular Disorder
Primary: Fatal and Nonfatal Ischemic Stroke in the Vertebrobasilar Territory — 72 Participants
N/A N=1,135 Protocol-guided Rapid Evaluation of Veterans Experiencing New Transient Neurological Symptoms
Transient Ischemic Attack · Stroke
Primary: Effectiveness: Without-fail Care Rate — 95; 363 Participants
N/A N=140 Reducing Risk of Recurrence
Stroke · TIA · Hypertension
Primary: Systolic Blood Pressure — 130.83; 133.67 mm Hg — p=0.29
Phase 2 N=50 TNK-tPA Evaluation for Minor Ischemic Stroke With Proven Occlusion
Ischemic Stroke
Primary: Number of Patients With Serious Bleeding Events — 0; 1 Participants
Phase 2 N=31 NeuroCognition After Carotid Recanalization
Cognition Disorder · Stroke · Occlusion Carotid
Primary: Change in Montreal Cognitive Assessment (MoCA) Score — 0.56; 1.38; -0.75; 0.50 score on a scale
Phase 3 N=3,876 Insulin Resistance Intervention After Stroke Trial
Stroke · Myocardial Infarction · Diabetes
Primary: Recurrent Fatal or Non-fatal Stroke, or Fatal or Non-fatal Myocardial Infarction — 175; 228 participants — p=.0067
N/A N=2 Pilot Study of Pre-Ischemic Conditioning for Intracranial Atherosclerosis
Intracranial Atherosclerosis
Primary: Percent Change in Cerebral Blood Flow (CBF) — 0; 25 percentage increase in CBF
Phase 2 N=18 Combination Anti-Platelet and Anti-Coagulation Treatment After Lysis of Ischemic Stroke Trial (CATALIST)
Ischemic Stroke
Primary: Symptomatic Intracerebral Hemorrhage (ICH) — 1; 1 participants
N/A N=160 Treatment With Intent to Generate Endovascular Reperfusion
Ischemic Stroke
Primary: Successful Reperfusion, Defined as mTICI Score ≥ 2b — 130 Participants
Phase 4 N=457 Trial of Cilostazol in Symptomatic Intracranial Arterial Stenosis II
Cerebral Infarction · Atherosclerosis
Primary: Number of Participants With Progression of Symptomatic Intracranial Stenosis — 20; 32 participants
Phase 2 N=15 Safety and Efficacy Study of a Protease Activated Receptor-4 Antagonist Being Tested to Reduce the Chances of Having Additional Strokes or "Mini Strokes"
Thrombosis
Primary: Number of Participants With Composite of Symptomatic Ischemic Stroke by Day 28 and Unrecognized Brain Infarction Assessed by MRI at Day 28
N/A N=35 Safety Study of Post Intravenous tPA Monitoring in Ischemic Stroke
Stroke · Ischemic Stroke
Primary: Number of Participants Needing ICU Care/Interventions Within the First 24 Hours of IV tPA Administration — 0 Participants
N/A N=31 Multifocal Brain Magnetic Stimulation in Chronic Ischemic Stroke
Stroke
Primary: Changes in Brain Activation — 48.5; -30 voxels
N/A N=76 Thrombolytic Care During Inter-hospital Transfer
Stroke
Primary: Percentage of Participants With a rtPA Protocol Violation — 7; 0 Participants
N/A N=55 The ENROUTE Transcarotid Neuroprotection System (ENROUTE Transcarotid NPS) DW-MRI Evaluation
Carotid Artery Diseases · Carotid Atherosclerosis · Carotid Stenosis
Primary: Incidence of Ipsilateral New White Lesions, by Patient — 12 Participants
Phase 2 N=30 Contrastim Stroke Trial
Stroke
Primary: Upper Extremity Fugl-Meyer Score — 23.8; 31.5; 31.9; 37 units on a scale — p=0.05
Phase 3 N=11,016 THALES - Acute STroke or Transient IscHaemic Attack Treated With TicAgreLor and ASA for PrEvention of Stroke and Death
Acute Ischaemic Stroke · Transient Ischaemic Attack
Primary: Composite of Subsequent Stroke or Death — 303; 362 Participants — p=0.015
Phase 4 N=60 Thrombectomy REvascularization of Large Vessel Occlusions in Acute Ischemic Stroke (TREVO)
Ischemic Stroke
Primary: Revascularization Status — 92 percentage of subjects TICI 2 or >
Phase 4 N=203 Effect of Cilostazol in the Acute Lacunar Infarction Based on Pulsatility Index of Transcranial Doppler
Cerebral Infarction
Primary: The Changes of Middle Cerebral Artery (MCA) and Basilar Artery (BA) Pulsatility Index (PI) at 14 and 90 Days From the Baseline Transcranial Doppler (TCD) Study — 0.07…
N/A N=252 Sleep Apnea in TIA/Stroke: Reducing Cardiovascular Risk With Positive Airway Pressure
Transient Ischemic Attack · Stroke
Primary: HOMA IR Change From Baseline — 0.9; 4.0; 4.1 HOMA-IR Index
Phase 3 N=451 Stenting vs. Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis
Ischemic Stroke
Primary: Any Stroke or Death Within 30 Days of Enrollment or Any Revascularization Procedure OR an Ischemic Stroke in the Territory of the Symptomatic Intracranial Artery Beyond…
N/A N=113,035 Alteplase in Elderly Acute Ischemic Stroke (AIS) Patients During Hospitalization
Stroke
Primary: All-cause Mortality During Hospitalization of Acute Ischemic Stroke (AIS) Patients — 2.6; 0.8 Percentage of participants
N/A N=16 American Heart Association- Stroke/Hypoxia Study
Stroke
Primary: Number of Participants With Adverse Events — 1; 11; 2; 10 Participants
N/A N=206 Clinical Mismatch in the Triage of Wake Up and Late Presenting Strokes Undergoing Neurointervention With Trevo
Ischemic Stroke
Primary: Weighted Modified Rankin Scale (mRS) Score, Lead Co-Primary Efficacy Outcome — 5.5; 3.4 score on a scale
Phase 2 N=277 Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke
Acute Ischemic Stroke
Primary: Percentage of Participants With Composite Global Measure of Functional Disability Excellent Outcome at Day 90 — 54.1; 41.5; 39.9 percentage of participants — p=0.086
Phase 3 N=363 LACunar Intervention (LACI-2) Trial-2
Cerebral Small Vessel Diseases · Stroke, Lacunar
Primary: Feasibility of Phase III Trial — 20; 21; 10; 4 Participants
N/A N=12,012 Vascular Ultrasound Screening in Patients With Ischemic Cerebrovascular Disease: a Multi-center Registry Study
Stroke
Primary: Evidence of Carotid Artery or Intracranial Artery Atherosclerosis Confirmed by Vascular Ultrasonography — 96; 1063; 826; 241 artery numbers